BioNTechBNTX
About: BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
Employees: 6,133
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
55% more capital invested
Capital invested by funds: $3.39B [Q2] → $5.24B (+$1.86B) [Q3]
17% more first-time investments, than exits
New positions opened: 76 | Existing positions closed: 65
17% more funds holding in top 10
Funds holding in top 10: 6 [Q2] → 7 (+1) [Q3]
16% more call options, than puts
Call options by funds: $367M | Put options by funds: $317M
4% more funds holding
Funds holding: 281 [Q2] → 292 (+11) [Q3]
0.89% more ownership
Funds ownership: 17.72% [Q2] → 18.61% (+0.89%) [Q3]
22% less repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 93
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
10 analyst ratings
Wells Fargo Mohit Bansal 24% 1-year accuracy 6 / 25 met price target | 50%upside $170 | Overweight Initiated | 11 Dec 2024 |
Canaccord Genuity William Maughan 0% 1-year accuracy 0 / 1 met price target | 52%upside $171 | Buy Maintained | 27 Nov 2024 |
JP Morgan Jessica Fye 39% 1-year accuracy 16 / 41 met price target | 8%upside $122 | Neutral Maintained | 26 Nov 2024 |
Evercore ISI Group Cory Kasimov 21% 1-year accuracy 3 / 14 met price target | 11%upside $125 | Outperform Upgraded | 19 Nov 2024 |
Canaccord Genuity John Newman 52% 1-year accuracy 14 / 27 met price target | 51%upside $171 | Buy Maintained | 18 Nov 2024 |
Financial journalist opinion
Based on 6 articles about BNTX published over the past 30 days
